Details
| Stereochemistry | RACEMIC |
| Molecular Formula | 2C10H20NO4.C10H6O6S2 |
| Molecular Weight | 722.821 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(OC(C)=O)C(=O)OCC[N+](C)(C)C.CC(OC(C)=O)C(=O)OCC[N+](C)(C)C.[O-]S(=O)(=O)C1=CC=CC2=C1C=CC=C2S([O-])(=O)=O
InChI
InChIKey=HELVYVGHOJPCEV-UHFFFAOYSA-L
InChI=1S/2C10H20NO4.C10H8O6S2/c2*1-8(15-9(2)12)10(13)14-7-6-11(3,4)5;11-17(12,13)9-5-1-3-7-8(9)4-2-6-10(7)18(14,15)16/h2*8H,6-7H2,1-5H3;1-6H,(H,11,12,13)(H,14,15,16)/q2*+1;/p-2
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effect of a new synthetic cholinergic compound (aclatonium napadisilate) on interdigestive motility and pancreatic function in humans. | 1989-10 |
|
| Effect of acetylcholine and new cholinergic derivative on amylase output, insulin, glucagon, and somatostatin secretions from perfused isolated rat pancreas. | 1982-07 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2476520
Aclatonium should be given at the dosage of 300 mg/day.
Route of Administration:
Other
The effect of aclotonium on exocrine pancreatic secretion and insulin release was investigated in the isolated, perfused rat pancreas. The effect of the drug on insulin release was detectable at a concentration of 0.1uM, while the increase in exocrine secretion was observed at 1.0 uM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47796
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
YX23434YHQ
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
55077-30-0
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
C91037
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
6918580
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
4832
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
100000084606
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110902
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
SUB05244MIG
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
DTXSID7048665
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | |||
|
m1375
Created by
admin on Mon Mar 31 18:47:08 GMT 2025 , Edited by admin on Mon Mar 31 18:47:08 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD